Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human ...

Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for ...
inc42

Edapt - Latest News, Analysis, Funding, Financials & More

Founded in 2017, Edapt operates in Edtech offering technology education designed to empower students of all ages with essential skills for the Fourth Industrial ...
Daily Mail

One in seven teachers at secondary schools have faced an allegation from a pupil or parent in the past year, survey reveals

One in seven secondary school teachers have faced an allegation from a pupil or parent in the past year. A survey of almost 8,000 staff found 14 per cent had been subjected to such accusations. Many ...
inc42

Edapt - Company Profile & Overview

Founded in 2017, Edapt operates in Edtech offering technology education designed to empower students of all ages with essential skills for the Fourth Industrial ...
manilatimes

Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies

Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025 ...
PharmiWeb

Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025

A novel bispecific T cell engager for the treatment of solid tumors that express DARKFOX TM, a previously undiscovered antigen derived from an alternative open reading frame of FOXM1. Abstract number: ...